knowledge -WSS

knowledge

author：explore 2025-09-05 06:04:49 - browse：2

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

WSS

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Lab trade group sues FDA to halt regulation of lab

Antibiotic resistance nearly killed me, so I'm raising awareness of it

EPA limits use of carcinogenic gas for sterilizing medical devices

AI used to predict Covid

What will save rural psychiatry services? Higher Medicaid payments

explore

knowledge

focus

Medicare details structure of new drug price negotiation program

Latest bird flu infection made farmworker sicker than earlier cases

Hollywood unions extend contract negotiations for actors

Medicare coverage of Wegovy, once blocked, now looks possible

As demand for Covid shots wanes, Moderna seeks its next success

Focused ultrasound for uterine fibroids: an uphill battle

Bright Health sells Medicare Advantage business to Molina

David Sabatini, ex

Medical leaders decry Supreme Court decision on affirmative action

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

entertainment

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

WuXi out of biotech trade group, U.S. and China relations to blame

RaDonda Vaught links Vanderbilt hospital issues to patient death

WuXi out of biotech trade group, U.S. and China relations to blame

Focused ultrasound for uterine fibroids: an uphill battle

First U.S. drug developed to treat liver disease MASH is approved

hotspot

explore

hotspot

leisure time